在糖尿病中,他类药物的使用与抑郁症之间的关联
Qingqi Li1, Hongrong Wu2, Xueer Cao1
1Institute of Neuroscience, Hengyang Medical School, University of South China, Hengyang, PR China.
Journal of affective disorders
|January 10, 2024
概括
类固醇药物治疗可以减少糖尿病患者的抑郁症状. 长期使用,特别是阿托瓦斯塔丁,对患有抑郁症的糖尿病患者显示出最显著的益处.
科学领域:
- 医学研究 医学研究
- 流行病学 流行病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 抑郁症是一种普遍存在的心理健康状况.
- 患有糖尿病的人对抑郁症的倾向更高.
- 关于他类药物治疗对抑郁风险的影响,存在相互矛盾的证据.
研究的目的:
- 在糖尿病和非糖尿病人群中调查他类药物使用和抑郁症症状之间的关联.
- 评估他类药物治疗持续时间和特定类型的他类药物对抑郁风险的影响.
主要方法:
- 利用了2005-2018年国家健康和营养检查调查 (NHANES) 的数据.
- 使用加权多变量逻辑回归模型来评估抑郁症状的几率比率 (OR).
- 进行了分层分析,以比较糖尿病患者和非糖尿病患者的他类药物的效果.
主要成果:
- 与非糖尿病患者 (aOR 0.78,p=0.128) 相比,使用静止剂显著减少了糖尿病参与者的抑郁症状 (aOR 0.59,p=0.014).
- 糖尿病患者长期使用他类药物 (>5年) 显示抑郁症风险较低 (aOR为0.42,p=0.002).
- 阿托瓦斯塔丁在降低糖尿病 (aOR 0.49,p=0.018) 和非糖尿病 (aOR 0.58,p=0.033) 组中的抑郁症症状方面表现出有效性.
结论:
- 患有抑郁症的糖尿病患者可能从延长的他类药物治疗中受益.
- 建议阿托瓦斯塔丁和普拉瓦斯塔丁用于患有抑郁症症状的糖尿病患者.
更多相关视频
08:15Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
62
09:15Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
14.6K
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
664
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
664
01:19Psychoneuroimmunology: Diabetes and Cancer
29
Chronic stress has been linked to both the onset and progression of serious health conditions, including Type 2 diabetes and cancer. Type 2 diabetes, a widespread chronic illness, is closely associated with obesity and insulin resistance, both of which often worsen under stress. Studies indicate that men experiencing high levels of chronic stress face a 45% higher risk of developing diabetes compared to those with minimal stress. Stress triggers physiological responses that elevate blood...
29
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
204
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
204
01:23Antidepressant Drugs: MAOIs and Other Agents
237
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
237
01:23Dipeptidyl Peptidase 4 Inhibitors
188
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
188
01:18Depression: Overview
247
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
247